STOCK TITAN

Rani Therapeutics (RANI) CEO logs RSU-related tax share sales

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat reported a sale of 8,014 Class A shares at $1.41 on 2024-12-27 to cover tax withholding on restricted stock unit settlement. Between 2025-06-27 and 2026-06-27, an additional 52,001 shares were withheld or surrendered to satisfy RSU-related tax withholding obligations. The report states these transactions were filed late due to inadvertent administrative oversight and notes that reported holdings include 12,343 shares held by VH Moll, L.P., for which Talat disclaims beneficial ownership beyond his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Imran Talat
Role Chief Executive Officer
Sold 8,014 shs ($11K)
Type Security Shares Price Value
Tax Withholding Class A Common Stock F1, F4, F3 7,927 $0.74 $6K
Tax Withholding Class A Common Stock F1, F4, F3 9,099 $0.81 $7K
Tax Withholding Class A Common Stock F1, F4, F3 8,916 $1.13 $10K
Tax Withholding Class A Common Stock F1, F4, F3 7,906 $1.40 $11K
Tax Withholding Class A Common Stock F1, F4, F3 9,077 $0.48 $4K
Tax Withholding Class A Common Stock F1, F4, F3 9,076 $0.55 $5K
Sale Class A Common Stock F1, F2, F3 8,014 $1.41 $11K
Holdings After Transaction: Class A Common Stock — 434,736 shares (Direct)
Footnotes (4)
  1. F1. This transaction is being reported late due to inadvertent administrative oversight.
  2. F2. Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of the restricted stock units.
  3. F3. Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. F4. Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.
Sale shares 8014 shares Class A Common Stock sold on 2024-12-27 to cover RSU tax withholding
Sale price $1.41 per share Price for 8,014 Class A shares sold on 2024-12-27
Tax-withholding shares 52001 shares Total shares withheld or surrendered in six F-code transactions for RSU tax obligations
Tax-withholding transactions 6 Number of F-code dispositions used to satisfy RSU-related tax withholding
VH Moll, L.P. holdings 12,343 shares Shares held by VH Moll, L.P., with beneficial ownership disclaimed beyond pecuniary interest
restricted stock units financial
"tax withholding obligations in connection with the settlement and release of the restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"sale of shares to cover tax withholding obligations in connection with the settlement"
beneficial ownership financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider stock transactions did Rani Therapeutics (RANI) CEO Imran Talat report?

Imran Talat reported a sale of 8,014 Class A shares at $1.41 on 2024-12-27 and dispositions of 52,001 shares between 2025-06-27 and 2026-06-27. All transactions were tied to tax withholding on restricted stock unit settlements.

Was the 8,014-share RANI transaction by Imran Talat a discretionary sale?

The 8,014-share transaction on 2024-12-27, at $1.41 per share, is described as a sale of shares to cover tax withholding obligations connected to restricted stock unit settlement, rather than a discretionary sale unrelated to tax liabilities.

Were Imran Talat’s RANI Form 4 transactions reported on time?

No. A footnote states that each reported transaction "is being reported late due to inadvertent administrative oversight." This applies to the sale and all tax-withholding-related dispositions covered in this Form 4 filing.

What does the RANI Form 4 say about shares held by VH Moll, L.P.?

The filing notes that reported holdings include 12,343 shares held by VH Moll, L.P.. Imran Talat disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in that partnership.

Were Rani Therapeutics (RANI) CEO Imran Talat’s transactions under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not checked, and no footnote references such a plan. The reported sale and tax-withholding dispositions are therefore not identified as being made pursuant to a Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Imran Talat

(Last)(First)(Middle)
C/O RANI THERAPEUTICS LLC
2051 RINGWOOD AVE

(Street)
SAN JOSE CALIFORNIA 95131

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
12/27/2024
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock12/27/2024(1)S(2)8,014D$1.41486,737(3)D
Class A Common Stock06/27/2025(1)F(4)9,076D$0.55477,661(3)D
Class A Common Stock09/27/2025(1)F(4)9,077D$0.48468,584(3)D
Class A Common Stock12/27/2025(1)F(4)7,906D$1.4460,678(3)D
Class A Common Stock03/22/2026(1)F(4)8,916D$1.13451,762(3)D
Class A Common Stock03/27/2026(1)F(4)9,099D$0.81442,663(3)D
Class A Common Stock06/27/2026(1)F(4)7,927D$0.74434,736(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction is being reported late due to inadvertent administrative oversight.
2. Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of the restricted stock units.
3. Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
4. Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.
/s/ Talat Imran07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)